Last reviewed · How we verify
HSG4112
At a glance
| Generic name | HSG4112 |
|---|---|
| Also known as | 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol |
| Sponsor | Glaceum |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients (PHASE2)
- A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses (PHASE1)
- A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients (PHASE2)
- A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112 (PHASE1)
- A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112 (PHASE1)
- A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |